← Research library

Cerebrolysin in vascular dementia: three years of observation

Observational study · 2011

What was studied
48 patients in Irkutsk with vascular dementia, 25 mild and 23 moderate at enrollment. Both groups received Cerebrolysin.
Main finding
At three years, mean MMSE changed from 22.1 to 25.8 in the mild group and from 15.8 to 17.3 in the moderate group. The mild-group change was significant in the published table.

MMSE at 36 months, mild dementia · 22.1 ± 3.8 → 25.8 ± 4.8 points · Significant versus baseline in the article table

Reported findings and study design

Prospective follow-up by baseline severity. The investigators measured cognition, function and reported adverse effects over 36 months.

Population or model 48 patients in Irkutsk with vascular dementia, 25 mild and 23 moderate at enrollment. Both groups received Cerebrolysin.

Dose, route and schedule

Five four-week courses over 36 months. Each course comprised 20 intravenous infusions of 20 mL Cerebrolysin in 100 mL isotonic saline.

Protocol source ↗ · Original journal PDF, methods and MMSE table.

Results · Original journal PDF, methods and MMSE table.
MeasureResultComparison, timing and statistics
MMSE at 36 months, mild dementia22.1 ± 3.8 → 25.8 ± 4.8 pointsSignificant versus baseline in the article table
MMSE at 36 months, moderate dementia15.8 ± 2.6 → 17.3 ± 3.5 pointsThe article table does not mark this comparison significant

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • No untreated comparator. These patients had vascular dementia, a different diagnosis from amnestic mild cognitive impairment and Alzheimer’s dementia.

Source details

Original journal PDF, methods and MMSE table.

Sources checked

Citation

Uncontrolled human reportFull text available

I. A. Suvorova. Cerebrolysin in vascular dementia: three years of observation Bulletin of Siberian Medicine. 2011;(2):92–97.

Study source ↗ · DOI 10.20538/1682-0363-2011-2-92-97 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards